The trial showed that the drug operates as the company believed it would.
BiolineRX Ltd. (TASE:BLRX) has completed the interim trial for BL1020, a treatment for schizophrenia. The trial, designed to test the drug’s mechanism, was between the Phase I (safety) and Phase II (effectiveness) trials.
BiolineRX believes that BL1020 acts by blocking dopamine receptors in the brain. The interim trial indicated that the drug acts as the company’s believes, suggesting that it is an effective treatment for schizophrenia. The study also makes it possible to better estimate recommended dosages, and demonstrated that it is safe for use as the Phase I trial already indicated.
BiolineRX has said in the past that it wants to conduct as many tests as possible for BL1020 in the early stages, in order to rule out as many poor candidates as possible and to improve recruitment of the best candidates for advanced and costly trials.
Published by Globes [online], Israel business news - www.globes.co.il - on July 16, 2007
© Copyright of Globes Publisher Itonut (1983) Ltd. 2007